Advanced Malignancies Clinical Trials

A listing of Advanced Malignancies medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 112 clinical trials
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. …

measurable disease
pd-l1
cancer
erbb2
b-cell lymphoma
  • 2 views
  • 19 Jul, 2021
  • 13 locations
A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Background Metastatic urothelial carcinoma is lethal and has no cure. Response rates to current treatments are modest. Researchers want to find new strategies to treat the disease. In this study, they will test a drug called M7824. The drug is a new immunotherapy that blocks the pathways that cancer cells …

measurable disease
transitional cell carcinoma
gemcitabine
progressive disease
renal function
  • 0 views
  • 23 Jul, 2021
  • 1 location
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

This is a Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with small cell lung cancer or squamous non-small cell lung cancer who have progressed after 1 or 2 lines of therapies. The primary objectives of the study are …

measurable disease
nivolumab
liver metastasis
platinum-based chemotherapy
blood transfusion
  • 0 views
  • 19 Jul, 2021
  • 42 locations
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib

measurable disease
renal function
cancer
metastatic non-small cell lung cancer
chemotherapy regimen
  • 109 views
  • 15 Jul, 2021
  • 156 locations
  • 506 views
  • 28 Jul, 2021
  • 12 locations
Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients

This is a nationwide, multicenter, randomized, prospective, real-world study. The purpose of this study is to evaluate the effect and safety of Yangzheng Compound Mixture in the treatment of sleep disorder in cancer patients with Qi-Yin deficiency syndrome during chemotherapy.

  • 0 views
  • 28 Jul, 2021
  • 2 locations
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in subjects with metastatic pancreatic cancer.

measurable disease
gemcitabine
fluorouracil
leucovorin
adenocarcinoma
  • 63 views
  • 19 Jul, 2021
  • 28 locations
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who roll-over into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. …

major surgery
mk-3475
pembrolizumab
metastasis
  • 510 views
  • 22 Jul, 2021
  • 268 locations
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

measurable disease
mk-3475
solid tumor
pembrolizumab
cancer of the ovary
  • 16 views
  • 28 Jul, 2021
  • 148 locations
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

patients with advanced malignancies. The study design allows an investigation of optimal combination dose of ceralasertib with other anti-cancer treatments, with intensive safety monitoring to ensure the

  • 64 views
  • 26 Jul, 2021
  • 25 locations